Crestor vs Zetia: Titration Speed, Tolerability, and What Women Need to Know

How These Two Drugs Work Differently

Rosuvastatin and ezetimibe lower LDL cholesterol through completely separate mechanisms, which is exactly why they are often combined rather than swapped. Rosuvastatin blocks HMG-CoA reductase inside liver cells, slowing the liver's own cholesterol synthesis. Ezetimibe blocks the NPC1L1 transporter in the small intestine, reducing cholesterol absorption from food and bile. Because they act at different sites, their side-effect profiles, titration requirements, and relevance to specific female life stages differ in ways that matter when you and your clinician are deciding which drug, or which combination, belongs in your regimen.

The Mechanism Gap Matters for Women

Sex-based differences in lipid metabolism mean women are not simply smaller men in this clinical picture. Estrogen raises HDL and lowers LDL during the reproductive years, so cardiovascular risk accelerates sharply after menopause when estrogen falls. The Menopause Society notes that LDL rises by an average of 10 to 14 percent in the first two years after the final menstrual period. Statin therapy, particularly with a high-potency agent like rosuvastatin, addresses this rise directly. Ezetimibe's intestinal mechanism is unaffected by hormonal status, which makes it a consistent add-on regardless of where you are in the menopause transition.

Titration Speed: Crestor Requires Steps; Zetia Does Not

The single biggest practical difference is that ezetimibe has no titration schedule. You start at 10 mg and stay there. Rosuvastatin starts lower and may be stepped up over weeks to months depending on your LDL target and tolerance.

Crestor Titration Schedule

The FDA-approved prescribing information for rosuvastatin specifies a starting dose of 10 mg once daily for most adults, with a recommended 5 mg starting dose for women of Asian descent or those on certain interacting drugs. Doses can be increased to 20 mg and then to the maximum of 40 mg, with at least four weeks between dose changes to allow LDL to stabilize.

Women tend to reach higher rosuvastatin plasma concentrations than men at the same dose, a pharmacokinetic difference documented in population studies. This is not simply a weight effect. Female sex is an independent predictor of higher statin exposure, which is one reason the conservative 5 mg starting dose is often more appropriate for women who are sensitive to myopathy or who are lighter than 60 kg.

Zetia Titration Schedule

There is none. The FDA label for ezetimibe specifies 10 mg once daily with no dose-ranging required. Full LDL effect is generally seen within two weeks. This simplicity makes it attractive for women who prefer not to return for repeated lab checks during a dose-escalation sequence, and for clinicians managing complex regimens in perimenopausal patients who are already navigating multiple hormonal and metabolic changes.

LDL Reduction: How Much Can You Expect?

Rosuvastatin is a high-intensity statin at doses of 20 to 40 mg. At 10 mg it qualifies as moderate-intensity. The JUPITER trial randomized 17,802 apparently healthy adults with elevated high-sensitivity CRP to rosuvastatin 20 mg or placebo. Rosuvastatin reduced LDL by 50 percent (median LDL fell from 108 mg/dL to 55 mg/dL) and cut major cardiovascular events by 44 percent over a median follow-up of 1.9 years.

Ezetimibe alone produces a more modest reduction. In pooled data from the SHARP and IMPROVE-IT trials, ezetimibe monotherapy lowers LDL by approximately 18 to 20 percent. The IMPROVE-IT trial added ezetimibe 10 mg to simvastatin 40 mg versus simvastatin alone in 18,144 post-acute coronary syndrome patients. The combination reduced LDL to a median of 53.7 mg/dL vs 69.5 mg/dL and produced a 6.4 percent relative risk reduction in major cardiovascular events over seven years. The key takeaway for clinical practice: ezetimibe's absolute cardiovascular benefit is meaningful but additive, not standalone in high-risk settings.

Putting the Numbers Side by Side

| Parameter | Crestor 10 mg | Crestor 20 to 40 mg | Zetia 10 mg | |---|---|---|---| | LDL reduction | 45 to 48% | 50 to 55% | 18 to 20% | | Triglyceride reduction | 10 to 20% | 20 to 28% | 5 to 10% | | HDL increase | 8 to 14% | 8 to 14% | 1 to 3% | | Time to full effect | 2 to 4 weeks | 2 to 4 weeks per step | 2 weeks | | Titration steps needed | 1 to 3 | 1 to 3 | None |

Tolerability: Where Women Experience Differences

Women report statin-associated muscle symptoms at higher rates than men. A 2019 analysis published in JAMA Cardiology confirmed that female sex is an independent risk factor for statin-associated muscle symptoms (SAMS), with odds ratios roughly 1.5 to 1.7 times higher than in men. This is not imagined. Women have lower baseline creatine kinase levels, so clinicians interpreting a "normal" CK in a symptomatic woman need to apply sex-specific reference ranges.

Myopathy Risk

Rosuvastatin carries a class-level risk of myopathy and, rarely, rhabdomyolysis. The risk is dose-dependent and rises sharply at 40 mg. For women specifically, lower starting doses (5 mg) are advisable when any of the following apply: age over 65, low body weight, hypothyroidism (common in women), or concurrent use of cyclosporine, gemfibrozil, or certain HIV antiretrovirals.

Ezetimibe has no known muscle toxicity as monotherapy. When added to a statin, any muscle symptoms that develop are typically attributed to the statin component. This is a meaningful tolerability advantage if you have already experienced SAMS on a statin and your clinician is weighing whether to add ezetimibe vs push to a higher statin dose.

Liver Enzyme Elevation

Both drugs carry a low risk of transaminase elevation. Rosuvastatin causes clinically significant elevations (greater than three times the upper limit of normal) in roughly 0.1 percent of patients at doses up to 40 mg. Ezetimibe alone causes transaminase elevations in about 0.5 percent of patients. The combination raises that rate slightly but remains below 1 percent in most reported series.

GI Side Effects

Ezetimibe's intestinal mechanism can cause diarrhea, abdominal pain, and bloating in 3 to 4 percent of patients. Rosuvastatin's GI side-effect profile is generally mild and resolves with or without food. Women with irritable bowel syndrome or inflammatory bowel disease should flag this with their prescriber, since ezetimibe's GI effects may be more noticeable in an already-sensitive gut.

New-Onset Diabetes Risk

Statins as a class carry a small but real risk of new-onset type 2 diabetes. A meta-analysis in The Lancet (2010) found one extra case of diabetes per 255 patients treated for four years across all statins. The risk is modestly higher with high-intensity statins, including rosuvastatin 20 to 40 mg. Women with PCOS, prediabetes, or postmenopausal insulin resistance face a higher baseline risk, so this matters more for them. Ezetimibe does not appear to increase diabetes risk.

Who This Is Right For, and Who Should Think Twice

The following framework is used by WomanRx clinicians to guide initial drug selection by life stage and risk profile. It is not a substitute for individualized clinical judgment.

Reproductive-Age Women (18 to 40)

If you are in your reproductive years and not using highly effective contraception, neither drug should be started without a confirmed negative pregnancy test and a reliable contraception plan. Statins are teratogenic (FDA pregnancy category X). Ezetimibe is pregnancy category C with animal data showing fetal harm. Both are contraindicated in pregnancy. For women in this age group whose LDL is elevated due to PCOS or familial hypercholesterolemia, ezetimibe is sometimes preferred because it is easier to stop quickly if pregnancy occurs and because the contraception conversation with rosuvastatin is more urgent given its teratogenicity.

Women with PCOS often have elevated LDL and triglycerides alongside insulin resistance. ACOG Practice Bulletin 194 on PCOS acknowledges that cardiovascular risk management is a long-term concern in this population. Rosuvastatin is effective here, but the diabetes-risk signal deserves attention given existing insulin resistance.

Perimenopausal Women (40 to 55)

LDL rises during perimenopause even without dietary change. The perimenopausal years are often when statin therapy is first recommended. Rosuvastatin at 5 to 10 mg is a reasonable starting point if LDL is above the threshold set by your 10-year ASCVD risk score. Titration from 5 mg to 10 mg can occur at four weeks if tolerance is good and LDL has not reached goal.

Perimenopausal women on systemic hormone therapy should note that estrogen-containing HRT modestly lowers LDL and raises HDL, so lipid goals may be achievable at lower statin doses. The interaction is pharmacodynamic rather than pharmacokinetic and does not change rosuvastatin dosing rules, but it may shift the calculus toward starting lower and assessing at four weeks rather than pushing to higher doses immediately.

Postmenopausal Women (55 and beyond)

Cardiovascular disease is the leading cause of death in postmenopausal women in the United States. The American Heart Association's 2021 Guideline on Primary Prevention identifies statin therapy as the cornerstone of lipid-lowering in high-risk patients. For postmenopausal women with established ASCVD or a 10-year risk above 7.5 percent, high-intensity rosuvastatin (20 to 40 mg) is generally preferred over ezetimibe monotherapy because the LDL reduction is substantially larger.

Ezetimibe added to rosuvastatin is a well-supported strategy when LDL remains above goal on maximally tolerated statin therapy alone. The IMPROVE-IT data, though collected in a post-ACS population that skewed male (about 76 percent), showed consistent benefit across sexes in subgroup analyses.

Women with Hypothyroidism

Hypothyroidism raises LDL independently and is far more common in women than men. A CDC analysis found that women are five to eight times more likely to have hypothyroidism. Uncontrolled hypothyroidism also increases myopathy risk from statins. Before starting or uptitrating rosuvastatin, confirm that thyroid-stimulating hormone is within the normal range. If TSH is elevated, treat the hypothyroidism first and recheck LDL at 6 to 8 weeks. The LDL may come down enough to reduce or defer statin initiation.

Switching from Crestor to Zetia: When and How

Switching entirely from rosuvastatin to ezetimibe rarely makes clinical sense for high-risk women, because the LDL reduction drops dramatically. A woman achieving 50 percent LDL reduction on rosuvastatin 20 mg would see her LDL rise substantially if ezetimibe replaced it entirely.

The scenarios where a switch (or addition) is appropriate include the following.

True statin intolerance. If you have experienced confirmed SAMS on two or more statins, a trial of ezetimibe monotherapy is a reasonable and guideline-supported approach. The 2022 ACC/AHA Cholesterol Guideline explicitly addresses statin-intolerant patients and supports ezetimibe as an alternative.

Bridging during pregnancy planning. If you plan to conceive within the next six months, rosuvastatin must be stopped. Ezetimibe is not considered safe in pregnancy either, but its faster washout and lower teratogenic signal (compared with statins) sometimes make it part of a short-term bridging discussion. This decision must be made with your clinician, not independently.

Add-on, not replacement, for most women. The more common clinical action is adding ezetimibe 10 mg to an existing rosuvastatin dose when LDL remains above target. The combination is additive: expect an additional 18 to 20 percent reduction on top of whatever rosuvastatin has already achieved.

Pregnancy, Lactation, and Contraception: A Required Read

Both drugs are contraindicated in pregnancy. Do not take rosuvastatin or ezetimibe if you are pregnant or planning to conceive in the near term.

Rosuvastatin in Pregnancy

Rosuvastatin carries an FDA pregnancy category X designation. Statins inhibit the mevalonate pathway, which is required for fetal cholesterol synthesis during organogenesis. Case reports and registry data have associated first-trimester statin exposure with rare but serious congenital malformations, though causality is not definitively established given confounding. The FDA label for rosuvastatin states that the drug should be discontinued as soon as pregnancy is recognized. If you are of childbearing age and starting rosuvastatin, reliable contraception is required for the duration of treatment.

Ezetimibe in Pregnancy

Ezetimibe is pregnancy category C. Animal reproduction studies at doses 10 times the human dose showed skeletal effects. No adequate and well-controlled human studies exist. Because cholesterol and products of cholesterol synthesis are necessary for normal fetal development, ezetimibe should not be used in pregnancy unless the benefit clearly outweighs a risk that has not been quantified in humans. This is an area where the evidence gap is real, and clinicians are extrapolating from animal data and mechanism, not from human trial data.

Lactation

Neither rosuvastatin nor ezetimibe has adequate lactation safety data. Rosuvastatin is detected in rat breast milk. Human breast milk transfer data are absent. Given that infants have no need for LDL-lowering therapy and that cholesterol is essential for neonatal brain development, both drugs should be avoided during breastfeeding. Lipid management in the postpartum period can generally be deferred until after weaning, unless cardiovascular risk is very high.

Contraception Requirement

Any woman of reproductive potential starting rosuvastatin should be counseled to use a reliable method of contraception, defined as methods with a failure rate below 1 percent with typical use: oral contraceptive pills, IUD (hormonal or copper), implant, or sterilization. This counseling should be documented. Women using combined hormonal contraceptives should also note that certain oral contraceptives modestly raise triglycerides, which is relevant if hypertriglyceridemia is part of the lipid picture alongside elevated LDL.

The Evidence Gap for Women

Women have been consistently underrepresented in cardiovascular outcome trials. In the JUPITER trial, women made up approximately 38 percent of enrollees. The IMPROVE-IT trial was about 24 percent female. This matters because the cardiovascular event rate in women is lower at younger ages, making trials underpowered to detect sex-specific differences in outcomes.

WomanRx editorial board member Dr. Elena Vasquez, MD, puts it plainly: "The LDL-lowering magnitude we see in trials is probably generalizable to women, but the absolute cardiovascular benefit numbers come mostly from male-dominated cohorts. When I counsel a 52-year-old woman in early menopause, I am partly extrapolating. She deserves to know that."

This is not a reason to avoid evidence-based therapy. It is a reason to have a specific, personalized conversation with your clinician rather than applying population-level risk estimates without adjustment.

Drug Interactions Specific to Women

Several drug interactions are more likely to arise in women's clinical contexts.

Cyclosporine: Used in autoimmune conditions more common in women (lupus, rheumatoid arthritis). Cyclosporine dramatically increases rosuvastatin plasma levels; the maximum rosuvastatin dose in patients on cyclosporine is 5 mg/day. Ezetimibe's AUC increases about two-fold with cyclosporine, requiring caution but not an absolute dose cap.

Combined hormonal contraceptives: Ethinyl estradiol-containing pills increase ezetimibe AUC by approximately 20 percent in pharmacokinetic studies. This is not considered clinically significant but should be noted in women who are also experiencing GI side effects.

Bile acid sequestrants (cholestyramine, colesevelam): Sometimes used in women with familial hypercholesterolemia or postmenopausal dyslipidemia. These reduce ezetimibe absorption by about 55 percent. Separate administration by at least four hours.

Fibrates (fenofibrate, gemfibrozil): Gemfibrozil is contraindicated with rosuvastatin above 10 mg due to myopathy risk. Fenofibrate is considered safer. Women with mixed dyslipidemia (high triglycerides and high LDL, common in PCOS) who need both lipid-lowering strategies should use fenofibrate over gemfibrozil if a fibrate is necessary.

Practical Monitoring Schedule

Once you and your clinician have chosen a regimen, the following schedule applies for most women.

At baseline: fasting lipid panel, AST/ALT, CK (sex-specific reference ranges), fasting glucose, TSH.

At four weeks: fasting lipid panel to assess initial response and determine whether titration is needed. No routine CK measurement unless you have muscle symptoms.

At 12 weeks: repeat fasting lipid panel after any dose change. Recheck glucose and liver enzymes if you had borderline values at baseline.

Annually: fasting lipid panel, glucose. Consider a formal cardiovascular risk reassessment every five years or when a major life-stage change occurs, such as menopause.

Women with PCOS or prediabetes should have fasting glucose or HbA1c checked every six months while on rosuvastatin given the diabetes-risk signal.